Gilead Sciences, Inc. (NASDAQ:GILD) and Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Wednesday entered into an exclusive option and license agreement to accelerate the development and commercialization ...
Architect Therapeutics Inc. has identified new spiro heterocyclic cyclin-dependent kinase 2 (CDK2) inhibitors potentially useful for the treatment of cancer, myeloproliferative, autoimmune disease, ...
WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet ...
WALTHAM, Mass.--(BUSINESS WIRE)--Ensem Therapeutics, Inc. today announced that its partner BeiGene has dosed the first five patients in its first-in-human Phase 1 trial to evaluate BG-68501, a small ...
The mitogen-activated protein kinase (MAPK) pathway integrates growth factor signaling through extracellular signal-regulated kinase (ERK) to control cell proliferation. To study ERK dynamics, many ...
This preclinical study explains the mechanism underlying CDK2 and CDK4/6 combination therapy, providing a blueprint for future clinical use These findings are notable because several CDK2 inhibitor ...
A phase II, multicenter, open-label study of polyPEPI1018 in combination with atezolizumab in participants with relapsed or refractory microsatellite-stable metastatic colorectal (MSS mCRC) cancer ...
Amid a flurry of dealmaking activity to start 2024, Allorion Therapeutics Inc., a 2020 startup based in Natick, Mass., and Guangzhou, China, has been extra busy. Two days after disclosing a potential ...
Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise its option on Kymera Therapeutics’ preclinical anticancer molecular glue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results